895 related articles for article (PubMed ID: 33662669)
21. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
Sun B; Hu N; Cong D; Chen K; Li J
Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
25. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
[TBL] [Abstract][Full Text] [Related]
26. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
27. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
[TBL] [Abstract][Full Text] [Related]
28. CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis.
Xu Q; Zhou L; Yang G; Meng F; Wan Y; Wang L; Zhang L
Cell Biol Int; 2020 Nov; 44(11):2344-2356. PubMed ID: 32808701
[TBL] [Abstract][Full Text] [Related]
29. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
30. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1).
Wang H; Zhu LJ; Yang YC; Wang ZX; Wang R
Br J Cancer; 2014 Jul; 111(2):339-54. PubMed ID: 24921914
[TBL] [Abstract][Full Text] [Related]
31. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
33. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
34. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin.
Liu Q; Wang K
Cell Biol Int; 2019 Nov; 43(11):1245-1256. PubMed ID: 30811078
[TBL] [Abstract][Full Text] [Related]
35. LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5.
Zhu Z; Shi Y; Gong X; Li J; Zhang M
Mol Biotechnol; 2022 Mar; 64(3):252-262. PubMed ID: 34595724
[TBL] [Abstract][Full Text] [Related]
36. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
37. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
38. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
39. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
